Related Experiment Video

Updated: May 8, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C

C Xu1, S Gupta, G Krishna

  • 1Merck Research Laboratories, Kenilworth, NJ, USA, rongxuus@yahoo.com.

European Journal of Clinical Pharmacology
|August 27, 2013
PubMed

Insights

This study characterized peginterferon alfa-2b pharmacokinetics in pediatric hepatitis C patients. Age and sex influenced drug disposition, supporting body size-adjusted dosing for children.

Area of Science:

  • Pharmacology
  • Hepatology
  • Pediatric Medicine

Background:

  • Chronic hepatitis C is a significant health concern in pediatric populations.
  • Peginterferon alfa-2b (PEG-IFN alfa-2b) is a key antiviral medication used in hepatitis C treatment.
  • Understanding drug disposition in children is crucial for optimizing therapy.

Purpose of the Study:

  • To characterize the population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C.
  • To identify patient-specific factors (covariates) that influence how PEG-IFN alfa-2b is processed by the body.
  • To inform appropriate dosing strategies for pediatric populations.

Main Methods:

  • A population pharmacokinetic nonlinear mixed-effects model was developed.
  • Data from 107 pediatric patients (aged 3-17 years) treated with PEG-IFN alfa-2b and ribavirin were analyzed.
  • A one-compartment model with first-order absorption and elimination was utilized.

Main Results:

  • A one-compartment model adequately described PEG-IFN alfa-2b pharmacokinetics.
  • Age and sex were identified as significant covariates affecting drug clearance and volume of distribution.
  • Body surface area normalized apparent clearance was consistent across pediatric age groups.

Conclusions:

  • PEG-IFN alfa-2b clearance and volume of distribution increase with age in pediatric patients.
  • The consistency of body size-normalized clearance supports using body size-adjusted dosing.
  • This pharmacokinetic characterization aids in optimizing PEG-IFN alfa-2b treatment for children with chronic hepatitis C.
Abstract

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...